Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancerin vitro

Abstract

Tamoxifen (TAM) remains the adjuvant therapy of choice for pre-menopausal women with ERα-positive breast cancer. Resistance and recurrence remain, however, a major challenge with many women relapsing and subsequently dying. The insulin-like growth factor (IGF) axis is involved in breast cancer pathogenesis and progression to endocrine resistant disease, but there is very little data on the expression and potential role of IGF-binding proteins (IGFBP) during acquisition of the resistant phenotype. The aim of this study was to determine the expression and functional role of IGFBP-2 and -5 in the development of TAM resistance (TamR) in vitro and to test retrospectively whether they were predictive of resistance in a tissue microarray of 77 women with primary breast cancers who relapsed on/after endocrine therapy and 193 who did not with long term follow up. Reciprocal expression of IGFBP-2 and IGFBP-5 was observed at both mRNA and protein level in TamR cells. IGFBP-2 expression was increased by 10-fold while IGFBP-5 was decreased by 100-fold, compared to TAM-sensitive control cells. shRNA-mediated silencing of IGFBP-2 in TamR cells restored TAM sensitivity suggesting a causal role for this gene in TamR. While silencing of IGFBP-5 in control cells had no effect on TAM sensitivity, it significantly increased the migratory capacity of these cells. Quantitative image analysis of immunohistochemical data failed, however, to demonstrate an effect of IGFBP2 expression in endocrine-relapsed patients. Likewise, IGFBP-2 and IGFBP-5 expression failed to show any significant associations with survival either in patients relapsing or those not relapsing on/after endocrine therapy. By contrast, in silico mining of a separate published dataset showed that in patients who received endocrine treatment, loss of expression of IGBP-5 was significantly associated with worse survival. Overall these data suggest that co-ordinated and reciprocal alteration in IGFBP-2 and −5 expression may play a role in the acquisition of endocrine resistance.

IGFBP2 plays an important role in heat shock protein 27-mediated cancer progression and metastasis

“…The correlation between cancer and IGFBP2 has seldom been mentioned previously. Some studies showed that the upregulation of IGFBP2 is often associated with aggressiveness and poor prognosis in glioblastoma and breast cancer through regulation of the β-catenin signaling pathway, which is also responsible for tumor invasion, proliferation and the maintenance of glioma stem cells [ 17 , 25 – 27 ]. In esophageal cancer, IGFBP2 overexpression is associated with shorter disease-free intervals and treatment resistance, and the knockdown of IGFBP2 sensitizes esophageal adenocarcinoma cells to cisplatin in a serum-dependent manner [ 28 ].…”

The role of BRCA1/2 in hereditary and familial breast and ovarian cancers

“…In Saudi Arabia, BC accounts for around 19.9% of women's deaths from cancer 27% of all newly diagnosed cancer, and is ranked first among cancer‐related deaths overall (Hawsawi et al, ). The high rate of mortality is due to the development of endocrine resistance and recurrence in BC, with many women relapsing and subsequently dying (Hawsawi et al, ). These figures present a major challenge in clinical research and for healthcare systems worldwide.…”

Characterization and Anticancer Potential of Silver Nanoparticles Biosynthesized from Olea chrysophylla and Lavandula dentata Leaf Extracts on HCT116 Colon Cancer Cells

“…The disease occurs as a result of tumor suppressor and/or oncogenic gene mutations that in turn leads to polyp's generation and eventually adenocarcinomas [5][6][7]. There are many toxic side effects that have impact on colon cancer patients due to the use of chemotherapeutic drugs because those drugs do not distinguish between normal and cancerous cells [8][9][10].…”